Denosumab, a powerful osteoporosis drug, acts as a monoclonal human antibody targeting the Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL), thereby inhibiting bone resorption [16]. The gene discussed is TNFSF11; the disease is osteoporosis.